このエントリーをはてなブックマークに追加
ID 32881
JaLCDOI
フルテキストURL
著者
Murakami, Takanori Himeji St. Mary’s Hospital
Ebara, Shin Okayama University
Saika, Takashi Okayama University
Irie, Shin Okayama Central Hospital
Takeda, Katsuji Kagawa Prefectual Hospital
Maki, Yoshio Konko Hospital
Miyaji, Sadayuki Kawasaki Medical School Hospital
Manabe, Daisuke Kagawa Prefectual Hospital
Kaku, Haruki Okayama University
Nasu, Yasutomo Okayama University Kaken ID researchmap
Tsushima, Tomoyasu National Okayama Hospital
Kumon, Hiromi Okayama University
抄録

We evaluated the need for transurethral biopsy at first follow-up after intravesical bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. The records of 84 patients with superficial bladder cancer who received a 6- or 8-week course of BCG were reviewed. Pathological results before BCG, cystoscopic findings, urinary cytology, and biopsy results for evaluation of BCG therapy were reviewed. All 19 patients with positive urinary cytology had evidence of positive bladder biopsy results. Fifty-three of 54 patients (98.1%) with no visible recurrent tumor and negative urinary cytology demonstrated negative pathological results on bladder biopsy. When not found in conjunction with positive urinary cytology, erythematous mucosa on cystoscopy was not an indicator of tumor recurrence or residual cancer. In conclusion, routine transurethral biopsy of the bladder for evaluating the response to BCG intravesical therapy is not necessary in patients who have no visible tumor on cystoscopy and negative urinary cytology./

キーワード
bladder cancer
BCG therapy
transurethral biopsy
cystoscopy
urinary cytology
Amo Type
Original Article
発行日
2007-12
出版物タイトル
Acta Medica Okayama
61巻
6号
出版者
Okayama University Medical School
開始ページ
341
終了ページ
344
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
publisher
査読
有り
PubMed ID